Literature DB >> 22207285

Antimicrobial susceptibility profiles associated with bacterial meningitis among children: a referral hospital-based study in Iran.

Mohammad Taghi Haghi-Ashtiani1, Setareh Mamishi, Nasrin Shayanfar, Masoud Mohammadpour, Bahareh Yaghmaei, Mina Abedini, Narges Node Farahani, Nima Rezaei.   

Abstract

Bacterial meningitis continues to be associated with high morbidity and mortality rate worldwide, especially in the pediatric age group. This study was performed to identify the microbial etiologies of meningitis among 31 children, who were admitted in the Emergency Ward of a referral pediatric hospital in Iran. Culture identification showed that Streptococcus pneumoniae (12 subjects), Haemophilus influenzae (11 subjects) were the most common bacteria, followed by Escherichia coli (7 cases) and Neisseria meningitidis (only one case). Antibiotic susceptibility tests revealed that vancomycin had the best effect on S. pneumoniae in comparison with other antibiotics, whereas H. influenzae and E. coli were more susceptible to ceftriaxone, ceftazidime, and ceftizoxime than other antibiotics. In conclusion, despite the advances in antibiotic therapy and vaccine development, bacterial meningitis still is a health problem. S. pneumoniae, H. influenzae, and N. meningitidis are the main sources of bacterial meningitis, but other organisms such as E. coli should also be suspected, when a case is admitted to a referral pediatric hospital.

Entities:  

Mesh:

Year:  2011        PMID: 22207285     DOI: 10.1556/AMicr.58.2011.4.3

Source DB:  PubMed          Journal:  Acta Microbiol Immunol Hung        ISSN: 1217-8950            Impact factor:   2.048


  1 in total

1.  Co-infection with dual Streptococcus pneumoniae serotypes as a cause of pediatric bacterial meningitis in Iran: a multi-center cross-sectional study.

Authors:  Sedigheh Rafiei Tabatabaei; Ahmadreza Shamshiri; Leila Azimi; Ali Nazari-Alam; Abdollah Karimi; Seyed Alireza Mirjavadi; Marjan Tariverdi
Journal:  BMC Infect Dis       Date:  2022-07-18       Impact factor: 3.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.